P1232: PRINCIPLES OF PRECISION ONCOLOGY IN PRIMARY REFRACTORY HIGH-GRADE B-CELL LYMPHOMA WITH MYC-, BCL2 AND/OR BCL6 REARRANGEMENTS (HGBL-DH/TH)

P1232: PRINCIPLES OF PRECISION ONCOLOGY IN PRIMARY REFRACTORY HIGH-GRADE B-CELL LYMPHOMA WITH MYC-, BCL2 AND/OR BCL6 REARRANGEMENTS (HGBL-DH/TH)

Bibliographic Details
Main Authors:	H. Witte, A. Faehnrich, J. Riedl, A. Kuenstner, J. Ketzer, N. von Bubnoff, H. Merz, H. Busch, A. Feller, N. Gebauer
Format:	Article
Language:	English
Published:	Wiley 2022-06-01
Series:	HemaSphere
Online Access:	http://journals.lww.com/10.1097/01.HS9.0000847792.93035.9d

Similar Items

Clinicopathological analysis of DLBCL/HGBL with MYC, BCL2 and BCL6 gene rearrangement
by: WEI Jing, HE Yaqi, XUE Tian, BAI Qianming, SHUI Ruohong, LU Hongfen, LI Xiaoqiu, YU Baohua
Published: (2023-09-01)

Mutational landscape of high-grade B-cell lymphoma with <i>MYC-</i>, <i>BCL2</i> and/or <i>BCL6</i> rearrangements characterized by whole-exome sequencing
by: Axel Künstner, et al.
Published: (2021-11-01)

Targeting MYC activity in double-hit lymphoma with MYC and BCL2 and/or BCL6 rearrangements with epigenetic bromodomain inhibitors
by: Weiping Li, et al.
Published: (2019-07-01)

Inferior survival in high-grade B-cell lymphoma with MYC and BCL2 and/or BCL6 rearrangements is not associated with MYC/IG gene rearrangements
by: Ellen D. McPhail, et al.
Published: (2018-11-01)

Limited stage high grade B-cell lymphoma with MYC, BCL2 and/or BCL6 rearrangements: BCL2 rearrangements drives the poor outcomes
by: Jennifer K. Lue, et al.
Published: (2024-10-01)

Plasmablastic lymphoma with MYC::IGH fusion and BCL2 rearrangement
by: Mohammad Barouqa, et al.
Published: (2022-08-01)

Targeted inhibition of DHODH is synergistic with BCL2 blockade in HGBCL with concurrent MYC and BCL2 rearrangement
by: Lin Liu, et al.
Published: (2024-06-01)

P1233: PRIMARY REFRACTORY PLASMABLASTIC LYMPHOMA: A PRECISION ONCOLOGY APPROACH
by: H. Witte, et al.
Published: (2022-06-01)

TDT Positive High-Grade Lymphoma with Myc, BCL2 And BCL6 Rearrangements: a Review of Diagnosis and Treatment
by: Aditi Singh, et al.
Published: (2022-02-01)

Targeting BCL2 with venetoclax is a promising therapeutic strategy for “double-proteinexpression” lymphoma with MYC and BCL2 rearrangements
by: Akiko Uchida, et al.
Published: (2019-07-01)

P1280: TARGETED INHIBITION OF DHODH IS SYNERGISTIC WITH BCL2 BLOCKADE IN LYMPHOMA WITH CONCURRENT MYC AND BCL2 REARRANGEMENT
by: W. Mo, et al.
Published: (2022-06-01)

Induction treatment in high-grade B-cell lymphoma with a concurrent MYC and BCL2 and/or BCL6 rearrangement: a systematic review and meta-analysis
by: Vanja Zeremski, et al.
Published: (2023-07-01)

P484: WHOLE EXOME SEQUENCING (WES) CHARACTERIZES THE MUTATIONAL LANDSCAPE OF BLASTIC PLASMACYTOID DENDRITIC CELL NEOPLASM (BPDCN)
by: H. Witte, et al.
Published: (2022-06-01)

Targeted next generation sequencing reveals high mutation frequency of CREBBP, BCL2 and KMT2D in high-grade B-cell lymphoma with MYC and BCL2 and/or BCL6 rearrangements
by: Solène M. Evrard, et al.
Published: (2019-04-01)

Redefining the high‐grade B cell lymphoma with double/triple rearrangements of MYC and BCL2/BCL6 genes. Learning from a case report
by: Socorro María Rodríguez‐Pinilla, et al.
Published: (2022-02-01)

High-grade B-cell lymphoma with MYC and BCL2 rearrangements arising in a composite lymphoma
by: Alison M. Moore, et al.
Published: (2018-05-01)

Prevalence and Prognostic Impact of MYC, BCL2, and BCL6 Rearrangements in Large B Cell Lymphoma Patients: A Multicenter Historical Cohort Study from Iran
by: Fatemeh Radmanesh, et al.
Published: (2024-04-01)

High-grade B-Cell lymphoma with MYC and BCL6 rearrangements associated with Richter transformation of chronic lymphocytic leukemia
by: Thomas S Rogers, et al.
Published: (2019-08-01)

P1190: OUTCOMES BY BCL2 AND MYC EXPRESSION AND REARRANGEMENTS IN UNTREATED DIFFUSE LARGE B-CELL LYMPHOMA FROM THE POLARIX TRIAL
by: F. Morschhauser, et al.
Published: (2022-06-01)

High‐grade B‐cell lymphoma with MYC and BCL2 rearrangements with abundant multinucleated giant tumor cells
by: Man Zhang, et al.
Published: (2023-05-01)

Correlation of c-MYC, BCL2 and BCL6 proteins overexpression with prognosis in Syrian DLBCL Patients
by: Sulaf Ahmad Farhat Maghrabi, et al.
Published: (2024-09-01)

CS2164 and Venetoclax Show Synergistic Antitumoral Activities in High Grade B-Cell Lymphomas With MYC and BCL2 Rearrangements
by: Delin Yuan, et al.
Published: (2021-03-01)

Primary cutaneous diffuse large B‐cell lymphoma, leg type with MYC/BCL2/BCL6 overexpression
by: Yosuke Okada, et al.
Published: (2022-02-01)

The survival impact of combined expression of myc, bcl2 and bcl6 in diffuse large b cell lymphoma patients
by: Adelina BIRCEANU COROBEA, et al.
Published: (2018-06-01)

Cutaneous manifestations as the presenting signs of diffuse large B-cell lymphoma/high-grade B-cell lymphoma with MYC and BCL2 rearrangements
by: Gabriela Piñero-Crespo, BS, et al.
Published: (2025-01-01)

Diffuse large B-cell lymphoma with concomitant c-MYC and BCL6 gene rearrangements with primary skin involvement: A case report and a review of literature
by: N G Gabeeva, et al.
Published: (2017-07-01)

Terminal deoxynucleotidyl transferase‐positive high‐grade B‐cell lymphoma with MYC and BCL2 rearrangements transformed from follicular lymphoma
by: Radu Chiriac, et al.
Published: (2024-12-01)

p53, Bcl-2 and C-Myc Expressions in Colorectal Carcinoma Associated with Schistosomiasis in Egypt
by: Khaled R. Zalata, et al.
Published: (2005-01-01)

Bcl-B: an “unknown” protein of the Bcl-2 family
by: N. V. Pervushin, et al.
Published: (2023-10-01)

Primary Diffuse Large B-Cell Lymphoma of the Breast with MYC and BCL2 Rearrangements with Terminal Deoxynucleotidyl Transferase Expression: A Case Report
by: Bassam Matar, et al.
Published: (2024-06-01)

Co-overexpression of bcl-2 and c-myc in uterine cervix carcinomas and premalignant lesions
by: Z. Protrka, et al.
Published: (2011-03-01)

MLL-rearranged acute lymphoblastic leukemias activate BCL-2 through H3K79 methylation and are sensitive to the BCL-2-specific antagonist ABT-199
by: Benito, J, et al.
Published: (2015)

HOW I TREAT DOUBLE-HIT LYMPHMOMA AND HGBL, NOS
by: Guilherme Duffles, et al.
Published: (2022-10-01)

DZNep-mediated apoptosis in B-cell lymphoma is independent of the lymphoma type, EZH2 mutation status and MYC, BCL2 or BCL6 translocations.
by: Chidimma Agatha Akpa, et al.
Published: (2019-01-01)

BCL-2 GENE REARRANGEMENT AND PROTEIN EXPRESSION IN PRIMARY CUTANEOUS B-CELL LYMPHOMAS
by: Pezzella, F, et al.
Published: (1994)

Detection of Protein BCL2/JH Rearrangement in Epidermoid Carcinomas of Mouth and Pharynx
by: Montovani, Jair, et al.
Published: (2010-09-01)

Clinicopathological features of lymphoma/leukemia patients carrying both BCL2 and MYC translocations
by: Naoto Tomita, et al.
Published: (2009-07-01)

Diffuse Large B-Cell Lymphoma in Kenya: MYC, BCL2, and the Cell of Origin
by: Jonathan Wawire, et al.
Published: (2019-04-01)

Differentiated approach in the treatment of diffuse large B-cell lymphoma according to c-MYC and BCL2 status
by: R. K. Karakulov, et al.
Published: (2022-01-01)

Correction: MYC Expression in Concert with BCL2 and BCL6 Expression Predicts Outcome in Chinese Patients with Diffuse Large B-Cell Lymphoma, Not Otherwise Specified
Published: (2014-01-01)